Looking at new data from the phase 3 PEARL trial, Dr. Melissa K. Accordino discusses how the use of CDK4/6 inhibitors could help patients with HR-positive/HER2-negative metastatic breast cancer move away from chemotherapy.
Melissa K. Accordino, MD, MS
Advertisement
Articles by Melissa K. Accordino, MD, MS
Advertisement
Latest Updated Articles
Moving Away from Chemotherapy to Treat HR-Positive/HER2-Negative Metastatic Breast CancerPublished: April 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Subcutaneous Keytruda in Adult and Pediatric Solid Tumors
2
Vaccine Elicits Immune Responses in Pancreatic Cancer
3
Advances in Kidney Cancer Allow Less Invasive and More Personalized Care
4
MNV-201 Secures FDA Fast Track Designation in Myelodysplastic Syndrome
5
